Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 46


Tau phosphorylation-associated spine regression does not impair hippocampal-dependent memory in hibernating golden hamsters.

Bullmann T, Seeger G, Stieler J, Hanics J, Reimann K, Kretzschmann TP, Hilbrich I, Holzer M, Alpár A, Arendt T.

Hippocampus. 2015 Sep 2. doi: 10.1002/hipo.22522. [Epub ahead of print]


Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.

Sinn M, Riess H, Sinn BV, Stieler JM, Pelzer U, Striefler JK, Oettle H, Bahra M, Denkert C, Bläker H, Lohneis P.

Eur J Cancer. 2015 Aug;51(12):1546-54. doi: 10.1016/j.ejca.2015.05.005. Epub 2015 Jun 3.


Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial.

Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, Müller L, Grunewald M, Stieler JM, Sinn M, Denecke T, Bischoff S, Oettle H, Dörken B, Riess H.

J Clin Oncol. 2015 Jun 20;33(18):2028-34. doi: 10.1200/JCO.2014.55.1481. Epub 2015 May 18.


Brain hypometabolism triggers PHF-like phosphorylation of tau, a major hallmark of Alzheimer's disease pathology.

Arendt T, Stieler J, Holzer M.

J Neural Transm (Vienna). 2015 Apr;122(4):531-9. doi: 10.1007/s00702-014-1342-8. Epub 2014 Dec 6.


Intensity-modulated and image-guided radiotherapy in patients with locally advanced inoperable pancreatic cancer after preradiation chemotherapy.

Sinn M, Ganeshan R, Graf R, Pelzer U, Stieler JM, Striefler JK, Bahra M, Wust P, Riess H.

ScientificWorldJournal. 2014;2014:452089. doi: 10.1155/2014/452089. Epub 2014 Oct 20.


α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study.

Sinn M, Denkert C, Striefler JK, Pelzer U, Stieler JM, Bahra M, Lohneis P, Dörken B, Oettle H, Riess H, Sinn BV.

Br J Cancer. 2014 Nov 11;111(10):1917-23. doi: 10.1038/bjc.2014.495. Epub 2014 Oct 14.


Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.

Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Görner M, Mölle M, Greten TF, Lakner V, Bischoff S, Sinn M, Dörken B, Pelzer U.

J Clin Oncol. 2014 Aug 10;32(23):2423-9. doi: 10.1200/JCO.2013.53.6995. Epub 2014 Jun 30.


KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.

Sinn BV, Striefler JK, Rudl MA, Lehmann A, Bahra M, Denkert C, Sinn M, Stieler J, Klauschen F, Budczies J, Weichert W, Stenzinger A, Kamphues C, Dietel M, Riess H.

Pancreas. 2014 May;43(4):578-83. doi: 10.1097/MPA.0000000000000077.


Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial.

Pelzer U, Hilbig A, Stieler JM, Bahra M, Sinn M, Gebauer B, Dörken B, Riess H.

BMC Cancer. 2014 Mar 19;14:204. doi: 10.1186/1471-2407-14-204.


Involvement of ESCRT-II in hepatitis B virus morphogenesis.

Stieler JT, Prange R.

PLoS One. 2014 Mar 10;9(3):e91279. doi: 10.1371/journal.pone.0091279. eCollection 2014.


SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.

Sinn M, Sinn BV, Striefler JK, Lindner JL, Stieler JM, Lohneis P, Bischoff S, Bläker H, Pelzer U, Bahra M, Dietel M, Dörken B, Oettle H, Riess H, Denkert C.

Ann Oncol. 2014 May;25(5):1025-32. doi: 10.1093/annonc/mdu084. Epub 2014 Feb 20.


[Multimodal treatment of pancreatic cancer].

Pelzer U, Sinn M, Stieler J, Riess H.

Internist (Berl). 2014 Jan;55(1):31-6. doi: 10.1007/s00108-013-3316-6. German.


[Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?].

Pelzer U, Sinn M, Stieler J, Riess H.

Dtsch Med Wochenschr. 2013 Oct;138(41):2084-8. doi: 10.1055/s-0033-1349608. Epub 2013 Oct 1. German.


Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study.

Sinn M, Striefler JK, Sinn BV, Sallmon D, Bischoff S, Stieler JM, Pelzer U, Bahra M, Neuhaus P, Dörken B, Denkert C, Riess H, Oettle H.

J Surg Oncol. 2013 Nov;108(6):398-402. doi: 10.1002/jso.23409. Epub 2013 Aug 23.


Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy.

Pelzer U, Hilbig A, Sinn M, Stieler J, Bahra M, Dörken B, Riess H.

Front Oncol. 2013 Jun 14;3:155. doi: 10.3389/fonc.2013.00155. eCollection 2013.


Biliary tract cancer: a survey regarding the current oncological daily care practice in Germany.

Sinn M, Bischoff S, Nehls O, Pelzer U, von Weizsäcker F, Kubicka S, Stieler JM, Caca K, Riess H.

Onkologie. 2012;35(12):755-60. doi: 10.1159/000345115. Epub 2012 Nov 20.


Role of human sec63 in modulating the steady-state levels of multi-spanning membrane proteins.

Mades A, Gotthardt K, Awe K, Stieler J, Döring T, Füser S, Prange R.

PLoS One. 2012;7(11):e49243. doi: 10.1371/journal.pone.0049243. Epub 2012 Nov 15.


L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial.

Kraft M, Kraft K, Gärtner S, Mayerle J, Simon P, Weber E, Schütte K, Stieler J, Koula-Jenik H, Holzhauer P, Gröber U, Engel G, Müller C, Feng YS, Aghdassi A, Nitsche C, Malfertheiner P, Patrzyk M, Kohlmann T, Lerch MM.

Nutr J. 2012 Jul 23;11:52. doi: 10.1186/1475-2891-11-52.


Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.

Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H.

Eur J Cancer. 2011 Jul;47(11):1676-81. doi: 10.1016/j.ejca.2011.04.011. Epub 2011 May 10.


First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group.

Pelzer U, Arnold D, Reitzig P, Herrenberger J, Korsten FW, Kindler M, Stieler J, Dörken B, Riess H, Oettle H.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1173-8. doi: 10.1007/s00280-011-1602-3. Epub 2011 Mar 15.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk